Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Albertsons Companies, Inc. (ACI) or Colgate-Palmolive (CL). But which of these two companies is the best option for those looking for undervalued stocks?
The mean of analysts' price targets for Albertsons Companies (ACI) points to a 36.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Besides Wall Street's top-and-bottom-line estimates for Albertsons Companies (ACI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended November 2025.
Albertsons Companies remains a ‘strong buy' due to deep undervaluation despite recent share price underperformance and margin pressure. Revenue is rising, driven by pharmacy and digital sales growth, but profitability is expected to decline as gross margins compress. Substantial share buybacks and prudent debt management could support EPS and improve capital allocation, even as net profits face headwinds.
While it may not be anything like the 7% to 8% inflation rate of 2022 and 2023, the consensus view is that inflation will remain above the Federal Reserve's preferred 2% target for some time to come. That makes dividend stocks more attractive, particularly those with yields that outpace the rate of inflation.
Investors with an interest in Consumer Products - Staples stocks have likely encountered both Albertsons Companies, Inc. (ACI) and BBB Foods (TBBB). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to potentially establish a registration study as a key value-driving catalyst. The company benefits from a robust pipeline, including partnerships with Takeda and Johnson & Johnson, and significant milestone opportunities.
TipRanks' ranking service highlights three dividend-paying stocks, including Valero Energy and Albertsons Companies.
Three key names in the technology, consumer staples, and financial sectors just announced substantial updates to their buyback plans. All three signal strong confidence in their business going forward, presenting potential opportunities for investors.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.